阿菲卡门特与梅托普罗罗尔对阻塞性多变性心肌病症患者报告的健康状况的影响
Michael E Nassif1, Pablo Garcia-Pavia2, Ahmad Masri3
1University of Missouri Kansas City Healthcare Institute for Innovations in Quality, and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Journal of the American College of Cardiology
|January 6, 2026
概括
与甲醇相比,Aficamten显著改善了阻塞性多变性心肌病 (oHCM) 患者的健康状况和生活质量. 这种心脏肌抑制剂为oHCM患者提供了一个有前途的治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 阻塞性缩性心肌病 (oHCM) 显著影响患者的生活质量.
- 目前的治疗方法旨在改善症状和运动能力.
- 在MAPLE-HCM试验中,心脏肌肉酶抑制剂Aficamten与美托普罗罗尔进行了比较.
研究的目的:
- 为了比较患者报告的aficamten与成年人症状性oHCM中metoprolol的健康状况益处.
- 评估症状,功能和生活质量的改善.
主要方法:
- 随机,双盲试验涉及175名患有症状的oHCM的成年人.
- 参与者接受了24周的aficamten或metoprolol单一治疗.
- 使用堪萨斯城心肌病问卷 (KCCQ) 和西雅图心痛问卷 (SAQ) 评估健康状况.
主要成果:
- 与美托普罗罗尔相比,Aficamten在KCCQ总体总结得分 (OSS) 中表现出明显更大的改善 (+7.8分;P < 0.001).
- 在接受aficamten治疗的患者中,更高的比例在KCCQ-OSS中经历了非常大的改善 (38.6%对18.4%).
- 此外,Aficamten还在SAQ物理限制量表上取得了显著的改进.
结论:
- 艾菲卡门在患有症状的oHCM患者的健康状况显著改善,超过了美托普罗罗尔.
- 阿菲卡门特显示出作为oHCM有效的初始治疗选择的潜力.
- 这些发现支持aficamten在提高oHCM患者的生活质量方面的作用.
更多相关视频
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
522
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
783
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
393
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
393
01:29Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:22Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
01:17Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K